The product which Mayne has hung it’s coat is without doubt Nextellis. This followed few years of Nuvaring since 2017. The project for sales ( they speak in Tongues is cycles ) 350,000. This has remained the same . Approximately $20m revenue. The original outlook for third year post approval FDA. was $200,000,000.00 . So their objective is 10% of original. Seriously $20m rev. with sales total supply, sales , marketing, and packaging along with shelf life failures of probably $70-80m the debt is being created while we speak.
MYX Price at posting:
22.8¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)